Drug intelligence / Profile preview

DS-112

Development stage: Preclinical
Lead developer: North Dakota State University
Modality: Small Molecules

Overview

DS-112 is a small molecule drug candidate that acts as an inhibitor of delta-5 desaturase (D5D), also known as fatty acid desaturase 1. The drug was initially developed by North Dakota State University and is currently being advanced by Dignity Sciences Ltd. Its primary therapeutic area is oncology, specifically for the treatment of solid tumors. As a D5D inhibitor, DS-112 targets the metabolic pathway involved in fatty acid synthesis and modification, which may play a role in tumor growth and survival. The compound remains in preclinical development with no reported clinical trials or approvals to date[1][5].

Targets

FADS1 (Fatty acid desaturase 1)

Beyond the preview

Go deeper on DS-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-112.

Explore the full profile